Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang · 2026
Read Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial by Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13580838.txt.
Description
Chunlin Zhou and fifteen co-authors published a randomized trial in twenty twenty-six testing two doses of the chemotherapy drug daunorubicin in acute myeloid leukemia patients aged fifty-five to sixty-five. Younger adults benefit from high doses and older patients get low ones, leaving this middle group uncertain. The single-center trial assigned patients to the standard or a raised dose, each with cytarabine.
After a median follow-up near three years, survival did not differ significantly between groups. Remission rates and measurable residual disease results were also alike, as were relapse-free and event-free survival. Infection patterns were broadly similar as well. The trial suggests the standard dose serves this age group as well as the higher one.
Catalog record
| CREATOR | Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |